Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (TWEYES)
A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Borgomanero, Italie, 28021
- Novartis Investigative Site
-
Galliate, Italie, 28066
- Novartis Investigative Site
-
Napoli, Italie, 80131
- Novartis Investigative Site
-
Napoli, Italie, 80132
- Novartis Investigative Site
-
Napoli, Italie, 80138
- Novartis Investigative Site
-
Pozzuoli, Italie, 80078
- Novartis Investigative Site
-
-
AL
-
Alessandria, AL, Italie, 15100
- Novartis Investigative Site
-
Casale Monferrato, AL, Italie, 15033
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italie, 60126
- Novartis Investigative Site
-
-
BA
-
Acquaviva delle Fonti, BA, Italie, 70021
- Novartis Investigative Site
-
Putignano, BA, Italie, 70017
- Novartis Investigative Site
-
Terlizzi, BA, Italie, 70038
- Novartis Investigative Site
-
-
BG
-
Bergamo, BG, Italie, 24127
- Novartis Investigative Site
-
-
BL
-
Belluno, BL, Italie, 32100
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Italie, 40138
- Novartis Investigative Site
-
-
BS
-
Brescia, BS, Italie, 25123
- Novartis Investigative Site
-
Desenzano del Garda, BS, Italie, 25015
- Novartis Investigative Site
-
-
BZ
-
Bolzano, BZ, Italie, 39100
- Novartis Investigative Site
-
-
CA
-
Cagliari, CA, Italie, 09124
- Novartis Investigative Site
-
-
CB
-
Larino, CB, Italie
- Novartis Investigative Site
-
-
CE
-
Caserta, CE, Italie, 81100
- Novartis Investigative Site
-
-
CH
-
Chieti, CH, Italie, 66100
- Novartis Investigative Site
-
-
CN
-
Ceva, CN, Italie, 12073
- Novartis Investigative Site
-
Cuneo, CN, Italie, 12100
- Novartis Investigative Site
-
-
CO
-
Como, CO, Italie, 22100
- Novartis Investigative Site
-
San Feramo Della Battaglia, CO, Italie, 22020
- Novartis Investigative Site
-
-
CT
-
Acireale, CT, Italie, 95024
- Novartis Investigative Site
-
Catania, CT, Italie, 95124
- Novartis Investigative Site
-
Catania, CT, Italie, 95123
- Novartis Investigative Site
-
-
CZ
-
Catanzaro, CZ, Italie, 88100
- Novartis Investigative Site
-
-
FC
-
Forlì, FC, Italie, 47100
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italie, 44100
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Italie, 71100
- Novartis Investigative Site
-
San Giovanni Rotondo, FG, Italie, 71013
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italie, 16132
- Novartis Investigative Site
-
Genova, GE, Italie, 16153
- Novartis Investigative Site
-
Rapallo, GE, Italie, 16035
- Novartis Investigative Site
-
-
KR
-
Crotone, KR, Italie, 88074
- Novartis Investigative Site
-
-
LE
-
Tricase, LE, Italie, 73039
- Novartis Investigative Site
-
-
LT
-
Terracina, LT, Italie, 04019
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Italie, 98125
- Novartis Investigative Site
-
Milazzo, ME, Italie, 98057
- Novartis Investigative Site
-
-
MI
-
Cinisello Balsamo, MI, Italie, 20092
- Novartis Investigative Site
-
Legnano, MI, Italie, 20025
- Novartis Investigative Site
-
Milano, MI, Italie, 20132
- Novartis Investigative Site
-
Milano, MI, Italie, 20122
- Novartis Investigative Site
-
Milano, MI, Italie, 20123
- Novartis Investigative Site
-
Milano, MI, Italie, 20100
- Novartis Investigative Site
-
Milano, MI, Italie, 20142
- Novartis Investigative Site
-
Rozzano, MI, Italie, 20089
- Novartis Investigative Site
-
Vizzolo Predabissi, MI, Italie, 20070
- Novartis Investigative Site
-
-
NU
-
Nuoro, NU, Italie, 08100
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italie, 90127
- Novartis Investigative Site
-
Palermo, PA, Italie, 90146
- Novartis Investigative Site
-
-
PC
-
Piacenza, PC, Italie, 29100
- Novartis Investigative Site
-
-
PD
-
Camposampiero, PD, Italie, 35012
- Novartis Investigative Site
-
Monselice, PD, Italie, 35043
- Novartis Investigative Site
-
Padova, PD, Italie, 35128
- Novartis Investigative Site
-
Padova, PD, Italie, 35100
- Novartis Investigative Site
-
-
PE
-
Pescara, PE, Italie, 65124
- Novartis Investigative Site
-
-
PG
-
Citta' di Castello, PG, Italie, 06012
- Novartis Investigative Site
-
Foligno, PG, Italie, 06034
- Novartis Investigative Site
-
Perugia, PG, Italie, 06100
- Novartis Investigative Site
-
-
PN
-
Pordenone, PN, Italie, 33170
- Novartis Investigative Site
-
-
PR
-
Parma, PR, Italie, 43100
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Italie, 27100
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria, RC, Italie, 89124
- Novartis Investigative Site
-
-
RE
-
Correggio, RE, Italie, 42015
- Novartis Investigative Site
-
Reggio Emilia, RE, Italie, 42123
- Novartis Investigative Site
-
-
RM
-
Civitavecchia, RM, Italie, 00053
- Novartis Investigative Site
-
Roma, RM, Italie, 00168
- Novartis Investigative Site
-
Roma, RM, Italie, 00161
- Novartis Investigative Site
-
Roma, RM, Italie, 00133
- Novartis Investigative Site
-
Roma, RM, Italie, 00184
- Novartis Investigative Site
-
Roma, RM, Italie, 00189
- Novartis Investigative Site
-
Roma, RM, Italie, 00186
- Novartis Investigative Site
-
-
RN
-
Riccione, RN, Italie, 47838
- Novartis Investigative Site
-
-
SA
-
Eboli, SA, Italie, 84025
- Novartis Investigative Site
-
Salerno, SA, Italie, 84131
- Novartis Investigative Site
-
-
SO
-
Sondrio, SO, Italie, 23100
- Novartis Investigative Site
-
-
SP
-
Sarzana, SP, Italie, 19038
- Novartis Investigative Site
-
-
SS
-
Sassari, SS, Italie, 07100
- Novartis Investigative Site
-
-
SV
-
Savona, SV, Italie, 17100
- Novartis Investigative Site
-
-
TA
-
Taranto, TA, Italie, 74100
- Novartis Investigative Site
-
-
TE
-
Teramo, TE, Italie, 64100
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italie, 10122
- Novartis Investigative Site
-
Torino, TO, Italie, 10153
- Novartis Investigative Site
-
Torino, TO, Italie, 10152
- Novartis Investigative Site
-
-
TR
-
Terni, TR, Italie, 05100
- Novartis Investigative Site
-
-
TS
-
Trieste, TS, Italie, 34129
- Novartis Investigative Site
-
-
TV
-
Conegliano, TV, Italie, 31015
- Novartis Investigative Site
-
Treviso, TV, Italie, 31100
- Novartis Investigative Site
-
-
UD
-
Udine, UD, Italie, 33100
- Novartis Investigative Site
-
-
VA
-
Busto Arsizio, VA, Italie, 21052
- Novartis Investigative Site
-
Somma Lombardo, VA, Italie, 21019
- Novartis Investigative Site
-
Varese, VA, Italie, 21100
- Novartis Investigative Site
-
-
VI
-
Santorso, VI, Italie, 36014
- Novartis Investigative Site
-
Vicenza, VI, Italie, 36100
- Novartis Investigative Site
-
-
VR
-
Legnago, VR, Italie, 37045
- Novartis Investigative Site
-
Negrar, VR, Italie, 37024
- Novartis Investigative Site
-
Verona, VR, Italie, 37126
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
Male or female patients aged 50 years or above Willing and capable to provide informed written consent Eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to wet AMD and/or Second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, whichever BCVA. In bilateral wAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab
Exclusion Criteria:
Active intraocular inflammation (grade trace or above) in either eye Any ocular or periocular active infection (current or suspected), e.g. conjunctivitis, keratitis, scleritis, uveitis, endophtalmitis, in either eye Risk factors for retinal pigment epithelial tear (including pigment epithelial retinal detachment) Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including cataract, retinal vascular occlusion, retinal detachment or macular hole Uncontrolled glaucoma in either eye (IOP ≥ 30 mmHg on medication or according to investigator's judgment) History of vitrectomy in the study eye History of stroke or transient ischemic attack Systemic treatment with any VEGF inhibitor in the 90 days prior to study enrollment Ocular treatment of the study eye with any anti-angiogenic drugs within 1 month prior to study enrollment Any intraocular surgery in the study eye within 28 days prior to enrollment Women of childbearing potential UNLESS using effective contraception during treatment Pregnant or lactating women Simultaneous participation in a study that includes administration of any investigational drug Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation Inability to comply with study procedures.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Ranibizumab
Administered as an Intravitreal injection
|
All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e.
stable VA for three consecutive monthly assessments performed while on ranibizumab treatment).
Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity.
Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Systemic Drug-related Adverse Events
Délai: Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
|
Number of Eyes With Ocular Drug-related Adverse Events
Délai: Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Number of Ranibizumab Injections
Délai: Baseline to month 12
|
Baseline to month 12
|
|
|
Time Interval Between Injections in Bilateral Disease
Délai: Baseline to month 12
|
Mean number of days between two consecutive injections per eye
|
Baseline to month 12
|
|
Mean Number of Injections Per Patient
Délai: Baseline to month 12
|
Number of injections per patient
|
Baseline to month 12
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CRFB002AIT02
- 2013-003333-15 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .